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Uveal melanoma cells use ameboid and
mesenchymal mechanisms of cell motility
crossing the endothelium
Michael D. Onkena,*, Kendall J. Blumerb, and John A. Coopera
a

Department of Biochemistry and Molecular Biophysics and bDepartment of Cell Biology & Physiology, Washington
University School of Medicine, Saint Louis, MO 63110

ABSTRACT Uveal melanomas (UMs) are malignant cancers arising from the pigmented layers
of the eye. UM cells spread through the bloodstream, and circulating UM cells are detectable
in patients before metastases appear. Extravasation of UM cells is necessary for formation of
metastases, and transendothelial migration (TEM) is a key step in extravasation. UM cells
execute TEM via a stepwise process involving the actin-based processes of ameboid blebbing
and mesenchymal lamellipodial protrusion. UM cancers are driven by oncogenic mutations
that activate Gαq/11, and this activates TRIO, a guanine nucleotide exchange factor for RhoA
and Rac1. We found that pharmacologic inhibition of Gαq/11 in UM cells reduced TEM. Inhibition of the RhoA pathway blocked amoeboid motility but led to enhanced TEM; in contrast,
inhibition of the Rac1 pathway decreased mesenchymal motility and reduced TEM. Inhibition
of Arp2/3 complex allowed cells to transmigrate without intercalation, a direct mechanism
similar to the one often displayed by immune cells. BAP1-deficient (+/–) UM subclones displayed motility behavior and increased levels of TEM, similar to the effects of RhoA inhibitors.
We conclude that RhoA and Rac1 signaling pathways, downstream of oncogenic Gαq/11,
combine with pathways regulated by BAP1 to control the motility and transmigration of
UM cells.
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INTRODUCTION
Uveal melanoma (UM) is a highly aggressive cancer arising in the
uveal layers of the eye, including the choroid, ciliary bodies, and iris.
The eye is the second most common site of melanoma. UM and
cutaneous melanoma are distinct diseases (van der Kooij et al.,
2019; Urtatiz et al., 2020). Oncogenesis of UM tumors is driven by
constitutive activation of the Gq family of alpha subunits, Gαq and
Gα11 (GNAQ and GNA11) in over 90% of tumors, while cutaneous
melanomas are driven by BRAF and NRAS mutations (Van Raamsdonk et al., 2009, 2010). Ten-year survival of patients with primary
UM tumors is about 50%, compared with over 90% for cutaneous
melanoma (Carvajal et al., 2017). Despite local control of the
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primary eye tumor being achieved in over 95% of patients, UM has
a high rate of metastasis and lethal outcome (Krantz et al., 2017).
The anatomy of the eye essentially prevents local spread, and the
posterior chamber of the eye lacks lymphatic vessels, so metastatic
spread of UM to distant organs occurs only through the bloodstream (Clarijs et al., 2001).
Hematogenous spread of UM cells begins with shedding of cells
from the primary eye tumor. The tumor vasculature of UM is irregular
and discontinuous, providing a poor barrier to cell shedding (Clarijs
et al., 2002; Mihic-Probst et al., 2012). As a result, circulating tumor
cells are found in all patients, even those with low-risk tumors that
do not develop metastatic disease (Keilholz et al., 2004; Callejo
et al., 2006; Anand et al., 2019). Because shedding of cells into the
blood is common, extravasation of circulating tumor cells out of
blood vessels at distant sites may be a key rate-limiting step for UM
metastasis.
To investigate transendothelial migration (TEM), we developed a
cell culture system employing primary human endothelial monolayers grown on polyacrylamide hydrogels, and we followed TEM in
real time with living cells (Onken et al., 2014b). Using this approach,
we discovered that the migration of UM cells occurs via a stepwise
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process (Onken et al., 2014a). Suspended UM cells attach to endothelial cells and then intercalate between adjacent endothelial cells,
flattening into the monolayer. UM cells remain intercalated for up to
several hours before releasing from the endothelial monolayer and
migrating underneath it. The cellular and molecular mechanisms
driving each step have not been characterized and may provide information for preventing circulating tumor cells from exiting the
vasculature.
Cell migration and the actin cytoskeleton are key features of
UM metastasis. Spread of UM tumors to distant organs is known to
be promoted by loss of BAP1, a chromatin remodeling factor
(Harbour et al., 2010), and we found that depletion of BAP1 increases the overall rate of TEM in our system (Onken et al., 2014a).
BAP1 is a histone deubiquitinase recruited to promoters of genes
(Yen et al., 2018), and we found that several actin cytoskeleton
regulator genes are targeted by BAP1 in UM cells (Yen et al.,
2018). In parallel, constitutively active Gq/11, the oncogenic driver
of UM, activates the dual nucleotide exchange factor TRIO, which
in turn activates the Rho-like small GTPases RhoA and Rac1
(Schmidt and Debant, 2014) that regulate the actin cytoskeleton
during cell migration (Feng et al., 2014, 2019). We hypothesize
that regulation of actin-based processes, downstream of BAP1
and Gq/11, and via the RhoA and Rac1 pathways, controls the
migration of UM cells.
Rac1 drives actin polymerization at the leading edge of a migrating cell and promotes focal complex assembly (Nobes and Hall,
1995; Parri and Chiarugi, 2010), resulting in the formation of lamellae and lamellipodia, which move the cell forward (Nobes and Hall,
1995, 1999; Parri and Chiarugi, 2010). Cell movement based on
Rac1-driven lamellipodial protrusions is often referred to as “mesenchymal” motility (Cooper et al., 2015; Byrne et al., 2016). Rac1 activates downstream effectors, including WAVE2, which activate
Arp2/3 complex for branched actin polymerization (Haga and Ridley, 2016). Rac1 also activates p21-activated kinase (PAK), which has
several important substrates (Bokoch, 2003; Zhao and Manser,
2012), including GEF-H1, a regulator of RhoA (Guilluy, Garcia-Mata,
and Burridge, 2011).
RhoA activates Rho-associated protein kinases 1 and 2 (ROCK1
and ROCK2) (Sanz-Moreno et al., 2008; Acton et al., 2014), which
increase actomyosin contractility via myosin light-chain (MLC)
phosphorylation. This results in increased cortical contractile
forces, which enhance membrane blebbing (Chrzanowska-Wodnicka and Burridge, 1996). Cell movement based on RhoA-driven
contractile blebbing is often referred to as “amoeboid” motility
(Cooper et al., 2015; Byrne et al., 2016). Biochemically, the RhoA
and Rac1 pathways can be antagonistic, with opposing roles in
cell migration (Sanz-Moreno et al., 2008; Guilluy et al., 2011).
ROCK signaling can antagonize Rac1 via ARHGAP22, and Rac1WAVE2 activity can antagonize ROCK signaling (Sanz-Moreno
et al., 2008). Interacting and antagonistic pathways downstream
of RhoA and Rac1 control switching between amoeboid and mesenchymal migration and have been identified in 2D and 3D culture conditions in normal fibroblasts and melanoma and breast
cancer cells (Cooper et al., 2015; Sander et al., 1999; Byrne et al.,
2016).
Here, we investigated the roles of these signaling pathways with
a combination of pharmacologic and molecular genetic perturbations, using direct live-cell observation of TEM. We found that UM
cells in suspension show predominantly amoeboid motility driven
by the RhoA pathway and that UM cells switch from amoeboid motility to mesenchymal motility as they adhere to and migrate through
the endothelial monolayer.
414 | M. D. Onken et al.

RESULTS
First, we established methods to quantify UM cell behavior during
TEM, allowing us to measure the effects of pharmacologic and genetic perturbations. We characterized the movements of two UM
cell lines, 92.1 and Mel202, before and during TEM from live-cell
movies (Figure 1A and Supplemental Video S1). UM cells displayed
amoeboid blebbing while in suspension, immediately after addition
to endothelial monolayers, and for a short while after coming to rest
on the monolayers. The cells continued blebbing during their initial
interactions with the endothelial monolayer. Next, they stopped
blebbing and formed lamellipodial protrusions. The cells proceeded
to spread, flatten, and intercalate themselves between endothelial
cells. The steps of adhesion and intercalation occurred relatively
quickly and were complete within a few hours. After a longer time,
the cells formed new lamellipodial protrusions that extended underneath the endothelial monolayer, and the cells migrated away, in
agreement with our previous observations (Onken et al., 2014a).
We quantified the progression of UM cells through each of these
steps during TEM (see Figure 1B for an example) by measuring and
calculating the following parameters: 1) total number of cells completing each step after 2 h (Figure 1C), 2) maximum instantaneous
rate of cells completing each step (Figure 1D), and 3) time required
for half the expected number of cells to complete each step (Figure
1E). The endothelial monolayers were prepared from primary human dermal microvascular endothelial cells (HDMVECs), for which
different lots display a certain level of biological variability. To account for this variability among lots, control (DMSO-treated) cell
samples were produced with every experiment, and the results from
these control samples were used to normalize the results from experimental samples.

Inhibition of the oncogenic driver Gq/11 blocks
transendothelial migration
Constitutively activating mutations in Gq/11 are the driving oncogenes for over 90% of UM tumors (Moore et al., 2016). Gq/11 activates the dual-GEF TRIO, which activates RhoA and Rac1 in UM cells
(Feng et al., 2014). We used FR900359, a potent inhibitor of Gq/11
in UM cells (Onken et al., 2018), to block TRIO activation by Gq. UM
cells treated with FR900359 for 24 h showed significant decreases in
progression for all steps of transmigration (Figure 1A and Supplemental Video S1). Adhesion and intercalation were reduced to 40%
of untreated activity, and neither extension nor migration was detected during any 2-h experiment (Figure 1C). Maximum rates of progression of each step decreased by >4-fold (Figure 1D), and time to
reach maxima increased by >2-fold (Figure 1E). Thus, inhibition of the
oncogenic driver mutation blocks most UM cells from transmigrating
and slows the progression of the few cells that do transmigrate.

Inhibition of the RhoA pathway increases transendothelial
migration
Activated TRIO regulates both RhoA and Rac1, which control opposing cell morphology pathways (Sanz-Moreno et al., 2008). We
interrogated each pathway independently to dissect their regulatory roles in UM cells during TEM. Inhibition of ROCK, the immediate downstream effector of activated RhoA, by Y-27632 blocked the
amoeboid blebbing activity of UM cells in suspension and on the
surface of the monolayers (Figure 2A and Supplemental Video S2).
Surprisingly, UM cells treated with Y-27632 showed significant increases in both the percentage of cells completing each step of
TEM (Figure 2B) and the rates of cells progressing through each
step (Figure 2, C and D). To confirm that these results were specific
to the Rho pathway and not caused by off-target effects of the
Molecular Biology of the Cell

Inhibition of the Rac1 pathway blocks
transendothelial migration

FIGURE 1: Quantification of TEM of untreated and FR900359-treated UM cells. (A) Frames from
representative movies of TEM by control 92.1 UM cells (upper panels and Supplemental Video
S1) and 92.1 cells treated with FR900359 (lower panels), at 20-min intervals. Scale bar = 50 µm.
(B) Cumulative percentage of cells undergoing each step of UM cell transmigration. Results are
from three 2-h movies for each condition for each cell line. The total numbers of 92.1 cells
scored were 321 (vehicle) and 486 (FR900359); the total numbers of Mel202 cells scored were
365 (vehicle) and 252 (FR900359). Curves from both cell lines under control and treated
conditions were quantified to generate the bar graphs in panels C-E (*p < 0.01). (C) Endpoint
values for each step after 2 h. (D) Maximum rate of each step calculated from the slope of the
tangent at the inflection point. (E) Time to reach half of the calculated maximum plateau for
each step.

inhibitor, we expressed a dominant-negative form of RhoA. For both
UM cell lines dominant-negative RhoA expression caused increases
in TEM similar to the effects of Y-27632 treatment (Figure 2, B–D).
Downstream of ROCK in the RhoA pathway is nonmuscle myosin
II, the motor protein that powers cellular contractility and membrane tension and thus drives amoeboid blebbing (Wyckoff et al.,
2006). Inhibition of nonmuscle myosin II in UM cells by treatment
with blebbistatin blocked blebbing activity (Figure 2A and Supplemental Video S2) and increased the rate of TEM (Figure 2, B–E).
These effects were similar to those of Y-27632. Thus, the effects of
ROCK inhibition on UM cells appear to occur through regulation of
actomyosin contractility.
Volume 32 March 1, 2021

Actin-based lamellipodial protrusions are a
prominent feature of UM cells as the cells
intercalate into the endothelial monolayer
and then extend below the monolayer and
migrate underneath it. We hypothesized
that these protrusions were driven by activation of Rac1. To inhibit Rac1, we treated
UM cells with NSC-23766, which blocks the
activation of Rac1 by exchange factors.
The cells showed increased amoeboid
blebbing and decreased lamellipodial protrusion, with an overall impairment of TEM
(Figure 3 and Supplemental Video S3). The
numbers of cells completing each step
were significantly reduced, as were the
rates of completion within each step
(Figure 3, B–D). To confirm that these results were specific to the Rac pathway and
not caused by off-target effects of the inhibitor, we expressed a dominant-negative
form of Rac1 in both UM cell lines. Mel202
UM cells expressing dominant-negative
Rac1 showed significant reduction of all
steps of TEM, similar to the effects of NSC23766 treatment. The effect on 92.1 cells
was a significant increase in the time for
completing each step (Figure 3, B–D).
Taken together, these decreases in TEM
parameters were similar to the stronger effects observed for cells treated with
FR900359 above (Figure 1, C–E).
Rac1 directly activates PAKs, which phosphorylate target proteins (Zhao and Manser,
2012). Treatment of UM cells with the PAK
inhibitor IPA-3 enhanced blebbing and reduced TEM (Figure 3, A and B), similarly to
NSC-23766. Fewer cells completed each
step, and rates of completion within each
step were reduced (Figure 3, C–E). Interestingly, UM cells treated with either NSC23766 or IPA-3 also showed larger blebs
and increased extracellular debris (Figure
3A and Supplemental Video S3) compared
with untreated cells (Figure 1A and Supplemental Video S1), suggesting dysregulation
of bleb size and retraction resulting from inhibition of the Rac pathway.

Inhibition of Arp2/3 complex: uveal melanoma cells
transmigrate and bypass intercalation
The actin-based protrusions that occur during lamellar and lamellipodial cell migration are driven by the rapid formation and growth
of branched actin networks at the cell periphery. Actin branching is
nucleated by the Arp2/3 complex, which is activated by the WAVE
complex, a downstream target of activated Rac1. We used the
Arp2/3 inhibitor CK-666 (Nolen et al., 2009) to interrogate the role
of branched actin formation in Rac1 regulation of TEM. UM cells
treated with CK-666 showed extensive blebbing, similar to the
effects of NSC-23766 and IPA-3 (Figure 4A and Video S4). The
CK-666–treated cells failed to switch from amoeboid blebbing to
Motility switch during transmigration
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2015). However, we were able to generate
two independent BAP1-deficient heterozygous subclones of the 92.1 UM cell line,
92.1-1D7 and 92.1-2D3. Both cell lines displayed amoeboid blebbing while in suspension, and they switched to forming lamellipodial protrusions during intercalation,
extension, and migration, similar to parental
BAP1(+/+) cells (Figure 5A and Supplemental Video S5). However, in contrast to parental BAP1 (+/+) cells, both BAP1 (+/–) subclones showed quantitative increases in all
steps of TEM. More cells completed all
steps, and the times for initiation and intercalation were shorter (Figure 5, C–E). Thus,
reduction of BAP1 activity produced effects
on TEM similar to those resulting from inhibition of the RhoA pathway, as opposed to
the effects of inhibition of the Rac1 pathway
(Supplemental Figure S2). These results suggest that BAP1 expression favors activation
of the RhoA pathway over the Rac1 pathway, such that loss of BAP1 shifts the balance toward Rac1-driven motility and increased TEM.

FIGURE 2: Effects of Rho pathway inhibition on TEM of UM cells. (A) Frames from
representative movies of TEM by 92.1 UM cells treated with RhoA-dependent ROCK1 inhibitor
Y-27632 (upper panels and Supplemental Video S2) or myosin inhibitor blebbistatin (lower
panels), at 20-min intervals. (B) Endpoint values of cells that have undergone each step of UM
cell transmigration treated with Y-27632 or blebbistatin, or expressing dominant negative RhoA,
based on results from three 2-h movies for each condition for each cell line. The total numbers
of 92.1 cells scored were 355 (vehicle), 502 (Y-27632), 285 (blebbistatin), and 103 (RhoA-DN); the
total numbers of Mel202 cells scored were 569 (vehicle), 172 (Y-27632), 700 (blebbistatin), and
151 (RhoA-DN). (C) Maximum rates for each step of TEM. (D) Times to reach half of the
calculated maximum plateaus. Inhibition of the Rho pathway causes more UM cells to
transmigrate and at a faster rate. Scale bar, 50 µm; *p < 0.01.

mesenchymal motility; however, they proceeded to perform TEM,
using a direct manner that bypassed the process of intercalation
(Figure 4A and Supplemental Video S4). This TEM migration behavior is similar to that displayed by immune cells, including lymphocytes and NK cells (Onken et al., 2014b).

Depletion of the metastasis suppressor BAP1 increases
transendothelial migration
Loss of the chromatin-remodeling factor BAP1 drives metastasis in
UM tumors (Harbour et al., 2010; Matatall et al., 2013). BAP1 is enriched at the transcriptional promoters of TRIO, cortactin, and several GTPase activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) in UM (Supplemental Figure S1A; Yen et al.,
2018), and several of these BAP1 targets are differentially regulated
in BAP1-deficient class 2 UM tumors (Supplemental Figure S1B;
Onken et al., 2004), which could alter the balance of RhoA and Rac1
pathways. We used CRISPR/Cas9 genome editing to generate
BAP1-deficient UM cells. The homozygous loss of BAP1 was lethal
in all of several UM cell lines tested, consistent with previous studies
(Testa et al., 2011; Dey et al., 2012; Matatall et al., 2013; Hart et al.,
416 | M. D. Onken et al.

DISCUSSION
Uveal melanoma cells switch modes of
motility during transendothelial
migration

UM cells perform TEM by a stereotypical
multistep route, which includes intercalation
of the UM cell into the endothelial monolayer (Onken et al., 2014a). Here, we discovered that UM cells exhibit both amoeboid
and mesenchymal modes of motility as they
migrate through the endothelium during
TEM and that the switch from amoeboid to
mesenchymal motility is an essential element of intercalation. Previous studies reported amoeboid and mesenchymal morphologies for cutaneous melanoma cells
attached to substrates with varying levels of adhesivity (Friedl and
Wolf, 2003; Sahai and Marshall, 2003; Sanz-Moreno et al., 2008,
2011); those studies did not involve melanoma cells interacting with
the endothelium.
We discovered that the oncogenic driver mutation of UM cells is
responsible for promoting TEM. Inhibition of constitutively active
Gq/11 in UM cells, by the pharmacologic inhibitor FR900359, led to
a nearly complete loss of TEM activity in our assay system. In our
previous work, FR900359 caused UM cells to stop dividing and to
re-differentiate towards their melanocytic state (Onken et al., 2018).
Together, the results suggest that FR900359 has promise as a novel
therapeutic agent for UM tumors. The inhibition of TEM observed
here may be particularly significant because the lethality of UM tumors is due to metastasis through the bloodstream (Anand et al.,
2019; Clarijs et al., 2001) and thus requires TEM.
We discovered that the Rho and Rac pathways activated downstream of the oncogenic mutation in UM cells have distinct and
complementary roles in the mechanism of transmigration. Inhibiting the Rho pathway blocked amoeboid motility but increased
TEM (Supplemental Figure S2), while inhibiting the Rac pathway
Molecular Biology of the Cell

tility and migration. In this case, the intercalation step was dispensable for TEM, and
the amoeboid mode of behavior alone was
sufficient. This finding suggests that UM
cells in situ may use a combination of amoeboid and mesenchymal modes of migration,
depending on the local circumstances, such
as the architecture of the vascular bed and
the flow of the bloodstream. One might
speculate that inside-out signaling from Rac
and PAK activates adhesion molecules on
the UM cell surface, such as integrin α4β1
(Rullo et al., 2012), required for adhesion to
endothelial cells (Onken et al., 2014a). This
hypothesis is supported by our observation
of decreased interactions of Rac/PAK-inhibited UM cells with the endothelial cell
monolayer, compared with untreated or
Arp2/3-inhibited UM cells.
Another possible explanation for the effect of Arp2/3 complex inhibition is a requirement for branched actin assembly to
stabilize early interactions that promote the
maturation of adhesive junctions. One
model of cell–cell adhesion formation is that
weak interactions at a small cell–cell contact
surface recruit active Rac1, which activates
actin assembly to expand the contact surface and form a mature adhesion (Collins
and Nelson, 2015). This model is based on
FIGURE 3: Effects of Rac pathway inhibition on TEM of UM cells. (A) Frames from
observations that Arp2/3 complex inhibition
representative movies of TEM by 92.1 UM cells treated with the RacGEF inhibitor NSC-23766
disrupts junction formation between cells
(upper panels and Supplemental Video S3) and the PAK inhibitor IPA-3 (lower panels).
on plastic but not the formation of cell ag(B) Endpoint values of cells treated with NSC-23766 or IPA-3, or expressing dominant negative
gregates (Collins and Nelson, 2015). Cells
Rac1, that have undergone each step based on results from three 2-h movies for each condition
that aggregate with neighboring cells do
for each cell line. The total numbers of 92.1 cells scored were 402 (vehicle), 297 (NSC-23766),
not require extensive Arp2/3-dependent la259 (IPA-3), and 138 (Rac1-DN); the total numbers of Mel202 cells scored were 641 (vehicle),
271 (NSC-23766), 417 (IPA-3), and 195 (Rac1-DN). (C) Maximum rates for each step. The number mellipodia activity, but cells that are flat and
of TEM events was too low to calculate maximum rates of migration. (D) Times to reach half of
spread out require expanded contacts
the calculated maximum plateaus. Inhibition of the Rac pathway caused fewer UM cells to
through lamellipodia, which would require
transmigrate and at a slower rate. The number of TEM events was too low to analyze extension
Arp2/3 activity (Collins et al., 2017). This
and migration accurately. Scale bar, 50 µm; *p < 0.01.
model predicts that blocking branched actin
formation by inhibiting Rac1 or PAK would
also prevent UM cells from establishing sufblocked mesenchymal motility and decreased TEM (Supplemental
ficiently strong adhesions with the endothelial monolayer. Our reFigure S2).
sults expand this view by suggesting that separate adhesive mechaWe propose the following model of TEM regulation in UM cells,
nisms exist, dependent on and independent of stabilization by actin
illustrated in Figure 6 and Supplemental Figure S3. First, UM cells
assembly during TEM.
display amoeboid morphology and motility as they flow through the
bloodstream and make initial contact with the endothelium. This
Metastasis-promoting BAP1 mutation favors mesenchymal
amoeboid behavior depends on active RhoA and actomyosin conmotility and increases transmigration
traction. Following contact with the endothelium, UM cells convert
We discovered that partial loss of BAP1, based on heterozygous
their morphology and motility to lamellar and lamellipodial protrugene deletion, caused increases in all steps of TEM. This discovery is
sions driven by Rac1. These protrusive actions enhance the interacimportant because in human UM patients, the loss of BAP1 is the key
tions of UM cells with the endothelial cells, which allows the UM cells
genetic feature associated with a high risk of metastasis in the class 2
to intercalate and flatten into the endothelium and then ultimately
lethal genotype (Harbour et al., 2010; Matatall et al., 2013). The clinileave the endothelium and migrate into surrounding tissues.
cal relationship of deletion of BAP1 to metastatic spread is consistent
with the biological connection of BAP1 function with the mechanism
Amoeboid and mesenchymal migration: complementary
of TEM discovered here. The genomic transcriptional targets of BAP1
roles for transendothelial migration
include a number of actin cytoskeleton genes, including TRIO, corUM cells treated with Arp2/3 complex inhibitor interacted with the
tactin, and various GAPs and GEFs (Figure S1A) (Yen et al., 2018).
endothelial monolayer and performed TEM, but the cells did not
BAP1 targets of particular note include ARHGAP18, a Rho-specific
switch from the amoeboid mode to the mesenchymal mode of moGAP, and ARHGEF4, a Rac/cdc42-specific GEF (Yen et al., 2018),
Volume 32 March 1, 2021
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Cell lines, plasmids, and viruses
Cells were cultured at 37°C in a humidified
5% CO2 incubator. Human 92.1 UM cells
(RRID: CVCL_8607) were the generous gift
of Martine Jager (Laboratory of Ophthalmology, Leiden University, Netherlands) and
were grown in RPMI 1640 medium (Life
Technologies, Carlsbad, CA) supplemented
with 10% FBS and antibiotics. Primary human dermal microvascular endothelial cells
(HDMVECs: HMVEC-dNeo, Catalog #CC2516; Lonza, Allendale, NJ) were grown in
EGM-2 MV culture medium (Lonza). HDMVECs were not used after eight passages.
BAP1(+/–) 92.1 subclone cell lines were generated using CRISPR/Cas9 genome editing
and sequence-verified by the Washington
University Genome Engineering and iPSC
Center (http://geic.wustl.edu). Briefly, single
guide RNAs were used to target Cas9 to
exon 3 of BAP1 in 92.1 cells to generate
frameshifted truncation mutants. The 1D7
strain is heterozygous for a 53-bp deletion:
p.V24fsX26 (c.183–237 delGTCAAGGGGG
T G C A A G T G G A G G A G AT C TA C G A 
CCTTCAGAGCAAATGTCAGGG) (Supplemental Figure S4). The 2D3 strain is
heterozygous for a 43-bp deletion:
FIGURE 4: Effects of Arp2/3 complex inhibition on TEM of UM cells. (A) CK-666 blocked the
p.K25fsX32 (c. 186–230 delAAGGGGGTGC
switch to lamellipodial activity, decreasing intercalation (upper panels and Supplemental Video
A A G T G G A G G A G AT C TA C G A C C T T
S4) and increasing direct transmigration bypassing intercalation (lower panels). (B) Endpoint
CAGAGCAAAT; Supplemental Figure S4).
values of cells that have undergone each step of transmigration based on results from three 2-h
Lentiviral-based constructs were used for
movies for each condition for each cell line. The total numbers of 92.1 cells scored were 321
cell
expression experiments. The pSLIK-DN(vehicle) and 360 (CK-666); the total numbers of Mel202 cells scored were 365 (vehicle) and 632
RhoA(T19N) dominant-negative YFP-fusion
(CK-666). (C) Maximum rates were decreased for intercalation but increased for migration.
expression construct was a gift from
(D) Times to reach half of the calculated maximum plateaus. Scale bar, 50 µm; *p < 0.01.
Sanjay Kumar (Addgene plasmid #84646;
RRID:Addgene_84646; MacKay and Kumar,
both of which are up-regulated in BAP1-deficient Class 2 human
2014). Viral production and infections were carried out according to
tumors (Onken et al., 2004; Supplemental Figure S1B). Concurrent
consortium recommendations (https://www.broadinstitute.org/rnaiup-regulation of ARHGAP18 and ARHGEF4 would be expected to
consortium/) using HEK293T cells transfected with third-generation
decrease RhoA signaling and increase Rac1 signaling and promote
lentivirus packaging plasmids, pMDLg/pRRE, pRSV-Rev, and
TEM. In support of this hypothesis, increased expression of ARHpMD2.G, using TransIT-LT1 transfection reagent (MirusBio, WisconGAP18 (Maeda et al., 2011; Humphries et al., 2017) and ARHGEF4
sin). Lentivirus supernatants were filtered with a 0.45-µm pore filter
(Taniuchi et al., 2018) has been linked to metastasis in other cancers.
(EMD Millipore Corp, USA) and concentrated at 20,000 rpm for 2 h.
Lentiviral particles were resuspended and stored in aliquots at
MATERIALS AND METHODS
–70°C. For protein expression, lentivirus was added directly to UM
Request a protocol through Bio-protocol.
cells grown in six-well plates containing 8 µg/ml protamine sulfate
(Sigma-Aldrich). After 36 h, the medium was changed to growth
Reagents and inhibitors
medium containing 200 ng/ml doxycycline hydrochloride (Alfa AeChemicals and reagents were obtained from Fisher Scientific (Pittssar, Ward Hill, MA) and incubated an additional 48 h to induce exburgh, PA) or Sigma-Aldrich (Saint Louis, MO), except as follows:
pression. Fusion protein expression was determined by presence of
Blebbistatin, Y-27632, NSC-23766, and IPA-3 were from Selleck
YFP during live-cell imaging. The pcDNA3-GFP-Rac1(T17N) domiChemicals (Houston, TX). FR900359 was prepared as described by
nant negative expression construct was purchased from Cell Biolabs
Onken et al. (2018). Inhibitors were dissolved in DMSO as stock solu(San Diego, CA, cat# STA-450) and transfected directly into 92.1
tions and frozen in small aliquots. For TEM experiments, Blebbistatin
and Mel202 cells using TransIT-LT1 transfection reagent (MirusBio,
and Y-27632 were used at 10 µM, IPA-3 was used at 30 µM, CK-666
Wisconsin). Fusion protein expression was determined by the preswas used at 100 µM, and FR900359 was used at 100 nM. Inhibitors
ence of GFP during live-cell imaging.
were tested for cell toxicity using a tetrazolium-based Cell Counting
Kit-8 (Bimake, Houston, TX), with treatment at working concentraImaging of live cells: transendothelial migration
tions for 12 h. In these assays, the inhibitors did not significantly rePolyacrylamide hydrogels were prepared with 0.4% bis-acrylamide
duce cell viability, with the exception of FR900359, which has longon glass-bottomed microwell dishes (MatTek, Ashland, MA) as determ effects that have been described elsewhere (Onken et al., 2018).
scribed by Onken et al. (2014b). The hydrogels were coated with
418 | M. D. Onken et al.
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HDMVEC monolayers were allowed to mature for 3 days before their use in TEM assays. Monolayers were inspected by phasecontrast microscopy to ensure that cells
covered the substrate completely, without
defects, before transmigration assays were
performed, as previously described (Onken
et al., 2014a,b). Monolayers were rinsed
with fresh EGM-2 MV media to remove
floating cells and debris 1 h before assaying
TEM.
UM cells were trypsinized, collected in
medium containing FBS to stop tryptic activity, and then centrifuged and resuspended in EGM-2 MV culture medium at
105 cells/ml. Inhibitors or vehicle were
added to individual aliquots of UM cells 2 h
before TEM imaging, except for FR900359,
which was added to stock plates 1 day before imaging (>24 h) and again after harvesting and resuspension in EGM-2 MV. For imaging, HDMVEC monolayers were placed in
an environmental chamber (Stage Top IncuFIGURE 5: BAP1-deficient UM cells show increases in all steps of TEM. (A) Frames from
bator, Tokai Hit, Shizuoka-ken, Japan) with
time-lapse movies of two independent BAP1(+/–) subclones of the UM 92.1 cell line: 2D3 (upper
5% CO2 at 37°C on an inverted microscope
panels and Supplemental Video S5) and 1D7 (lower panels). (B) Endpoint values of cells that
(Olympus IX72) and reassessed visually by
have undergone each step based on results from three 2-h movies for each cell line. The total
DIC to identify fields for imaging that were
numbers of cells scored were 395 (parental), 253 (2D3), and 203 (1D7). (C) Maximum rates for
absent of defects and showed visible junceach step. (D) Times to reach half of the calculated maximum plateaus. Scale bar, 50 µm;
*p < 0.01.
tions between all endothelial cells.
After monolayer integrity was confirmed,
104 UM cells were added to the monolayer
fibronectin (10 µg/ml in PBS) by incubation at 37°C for 30 min.
directly over the objective. DIC images were captured at 20-s interHDMVECs were plated onto the fibronectin-coated hydrogel subvals with a 10× objective. Scoring of TEM events was performed as
strates and incubated overnight to allow formation of monolayers.
described by Onken et al. (2014a). In DIC images, UM cells are round
and bright when added to the monolayers (for example, see Supplemental Figure S3, 5′). UM cells that interact with the top of the monolayer remain bright, even as they bleb and change shape (Supplemental Figure S3, 27′). At the initiation of transmigration, UM cells
send protrusions between cells in the endothelial monolayer, and the
distal portions of these protrusions become visible beneath the endothelial cells as flat, fanlike projections in DIC images (Supplemental Figure S3, 32′). The first frame with visible projections is scored as
the time of “initiation” for the associated UM cell. The transmigrating
UM cells then expand the opening in the endothelial junction and fill
the space between the endothelial cells by flattening and becoming
larger and less bright, resembling the adjacent endothelial cells in
DIC (Supplemental Figure S3, 50′). The first frame in which the UM
cell morphology stops changing and the cell settles among endothelial cells is scored as “intercalation.” Later, intercalated UM cells send
new protrusions that are visible as large flattened projections beneath the endothelial cells (Supplemental Figure S3, 89′); the first
frame in which this projection is visible is scored as “extension.”
Some UM cells proceed to extend this projection underneath the
monolayer, expanding and elongating the flattened protrusion. They
FIGURE 6: Diagram summarizing UM cell signaling and modes of
release their adhesions to the endothelial cells opposite the protrumotility during TEM. Constitutively active Gq, the oncogenic driver
sion and pull their cell body and nucleus beneath the monolayer, in
for UM, signals through the dual-GEF TRIO, which activates both
the direction of the leading protrusion (Supplemental Figure S3,
RhoA and Rac1. Rho signals through ROCK to myosin-II, which
102′). The first frame in which the UM cell nucleus is completely bepromotes amoeboid motility. Rac activates PAK and Arp2/3, which
neath the monolayer is scored as “migration” (Supplemental Figure
promote lamellar and lamellipodial protrusions as part of
S3, 108′). In the case of treatment with CK-666, UM cells that transmesenchymal motility. The switch from amoeboid to mesenchymal
migrated directly beneath the monolayer, without intercalating, were
motility increases the robustness of TEM, but TEM can occur via a
solely amoeboid mechanism.
only scored for “initiation” and “migration.”
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For dominant-negative expression experiments, epifluorescence
images were collected to detect cells expressing YFP (RhoA-DN) or
GFP (Rac1-DN) and only positive cells were analyzed by DIC imaging. To control for biological variability among different lots of primary human endothelial cells, DMSO-treated experiments were
performed with every inhibitor experiment, and data for each experimental condition were collected from three separate controlled
experiments.

Quantification and statistical analysis
Statistical analyses were performed with Prism (GraphPad, San Diego, CA). For endpoint cell counts, the mean and standard error of
the mean were calculated from at least three experiments for each
inhibitor, and statistical analysis compared each inhibitor experiment with control experiments from the same day. To generate cumulative percentage curves, data from all experiments for a given
inhibitor were combined, and these curves were used to quantify
rates. Nonlinear regression was used to fit curves for each step,
which extrapolated to maximal completion plateau values used to
quantify time to half maximal completion. To calculate maximum
rates, tangent lines were drawn either at the most vertical points of
curves that showed clear change over time or along the longest
linear stretch for curves that followed a more linear course. Times
and rates for each step were normalized to values generated from
control experiments run on the same day and 90% confidence intervals were calculated.
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